Clinical use of Hexabrix for radiological evaluation of leakage from the upper gastrointestinal tract based on experimental study.
The clinical use of Hexabrix (May and Baker) was started about 3.5 years ago for the radiological evaluation of patients in whom the possibility of leakage of contrast medium outside the upper gastrointestinal tract, particularly the oesophagus, was anticipated. The majority (greater than 70%) of the patients were in their early post-operative period. No adverse reactions because of the use of Hexabrix were encountered.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004064:Digestive System / Q000000981:diagnostic imaging* / Q000293:injuries; D004939:Esophageal Perforation / Q000000981:diagnostic imaging; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005260:Female; D005767:Gastrointestinal Diseases / Q000000981:diagnostic imaging; D006801:Humans; D007485:Ioxaglic Acid; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000000981:diagnostic imaging; D011859:Radiography; D012421:Rupture
D007485:Ioxaglic Acid